Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.

1 hour ago 1

Sara Appino, The Motley Fool

Wed, June 3, 2026 astatine 9:04 AM CDT 4 min read

Pivotal bioVenture Partners Investment Advisor accrued its presumption successful Trevi Therapeutics (NASDAQ:TRVI) during the archetypal quarter, acquiring 296,944 shares successful an estimated $3.32 cardinal commercialized based connected mean quarterly pricing, according to a May 14, 2026, SEC filing.

What happened

According to a SEC filing dated May 14, 2026, Pivotal bioVenture Partners Investment Advisor accrued its involvement successful Trevi Therapeutics (NASDAQ:TRVI) by 296,944 shares during the archetypal quarter. The estimated transaction worth was $3.32 million, calculated utilizing the mean unadjusted closing terms for the quarter. At 4th end, the money reported holding 1,553,726 shares, with a presumption worth of $18.54 million. The nett presumption worth accrued by $2.80 million, reflecting some stock purchases and banal terms appreciation.

What other to cognize

Pivotal bioVenture Partners' bargain brings its Trevi Therapeutics presumption to 6.63% of reportable AUM arsenic of March 31, 2026
Top holdings aft the filing:
- NASDAQ: PCVX: $79.75 cardinal (28.5% of AUM)
- NASDAQ: OCS: $44.68 cardinal (15.97% of AUM)
- NYSE: EVMN: $44.30 cardinal (15.8% of AUM)
- NASDAQ: ARQT: $31.94 cardinal (11.4% of AUM)
- NASDAQ: TRVI: $18.5 cardinal (6.6% of AUM)
As of May 13, 2026, Trevi Therapeutics shares were priced astatine $15.27, up 136.4% implicit the past year, outperforming the S&P 500 by 109.92 percent points.

Company Overview

Metric

Value

Price (as of marketplace adjacent 2026-05-13)	$15.27
Market Capitalization	$2.14 billion
Net Income (TTM)	($45.61 million)
One-Year Price Change	136.38%

Company Snapshot

Trevi Therapeutics focuses connected the improvement of Haduvio, an oral extended-release formulation of nalbuphine targeting superior neurologically mediated conditions specified arsenic chronic pruritus and chronic cough successful idiopathic pulmonary fibrosis.
The institution operates a clinical-stage biopharmaceutical model, generating worth done pharmaceutical probe and improvement with the purpose of aboriginal commercialization and licensing agreements.
Primary customers see healthcare providers, specialists, and patients affected by chronic neurological and pulmonary conditions, with a absorption connected underserved therapeutic markets.

Trevi Therapeutics is simply a clinical-stage biotechnology institution headquartered successful New Haven, Connecticut, with a strategical absorption connected advancing therapies for neurologically mediated diseases. The institution leverages its proprietary formulation, Haduvio, to code important unmet aesculapian needs successful chronic pruritus and chronic cough. Its competitory borderline lies successful its targeted attack and ongoing late-stage objective trials, positioning it to seizure worth successful specialized therapeutic areas.

Read Entire Article